{"version":1,"type":"story","url":"https://digestai.news/story/fda-seeks-feedback-on-real-world-testing-for-ai-medical-devices","json":"https://digestai.news/story/fda-seeks-feedback-on-real-world-testing-for-ai-medical-devices.json","markdown":"https://digestai.news/story/fda-seeks-feedback-on-real-world-testing-for-ai-medical-devices.md","slug":"fda-seeks-feedback-on-real-world-testing-for-ai-medical-devices","headline":"FDA seeks feedback on real-world testing for AI medical devices","summary":"The US Food and Drug Administration (FDA) is asking for public input on how to regulate AI-powered medical devices, which have rapidly expanded into clinics since ChatGPT’s 2022 release. Over 230 million people weekly now ask ChatGPT health-related questions, and AI tools now assist with drug prescriptions, X-ray interpretation, rare disease diagnosis, and administrative tasks like ordering lab tests. The FDA’s August discussion paper questions whether these devices—many of which influence clinical decisions—should face stricter oversight, including real-world testing and clinical trials, akin to drug approvals.\n\nCurrent regulations vary by risk level, but AI devices often lack real-world validation. A *Nature Medicine* review found only 23% of AI health studies used real-world patient data, and just 19 were prospective randomized trials. Critics argue simulated tests against human physicians are insufficient, while specialized medical AI models show inconsistent accuracy gains. The FDA and global counterparts are now debating whether AI devices should follow the same rigorous standards as drugs, given their potential impact on patient care and safety.","keyPoints":["FDA published an August discussion paper seeking feedback on AI medical device regulation by October 19","Over 230 million people weekly ask ChatGPT health-related questions, per OpenAI’s estimates","Only 23% of AI health studies used real-world patient data, per *Nature Medicine* review"],"whyItMatters":"Stricter real-world testing could improve AI medical device safety but may slow innovation. The FDA’s push for transparency and clinical trials aligns with public trust concerns, especially as AI tools increasingly influence diagnoses and treatments.","category":{"slug":"policy","name":"Policy & Regulation","url":"https://digestai.news/category/policy"},"entities":{"companies":["OpenAI","US Food and Drug Administration (FDA)"],"models":[],"people":[]},"firstPublishedAt":"2026-09-29T00:00:00Z","updatedAt":"2026-09-29T00:00:00Z","sourceCount":1,"hasPrimarySource":true,"sources":[{"outlet":"Nature Machine Learning","title":"AI-powered medical devices must be tested in real-world settings","url":"https://nature.com/articles/d41586-026-03046-7","publishedAt":"2026-09-29T00:00:00Z","type":"primary","primary":true,"lead":true}],"sourceNotes":null,"discussions":[],"thread":null,"cite":{"text":"Digest AI, \"FDA seeks feedback on real-world testing for AI medical devices\", 29 September 2026, https://digestai.news/story/fda-seeks-feedback-on-real-world-testing-for-ai-medical-devices","publisher":"Digest AI","title":"FDA seeks feedback on real-world testing for AI medical devices","datePublished":"2026-09-29T00:00:00Z","url":"https://digestai.news/story/fda-seeks-feedback-on-real-world-testing-for-ai-medical-devices"},"generatedBy":"Written by Digest AI's editorial model from the linked sources; the sources are the record.","license":"Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse"}